Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.

Hence, just like low haemoglobin levels (less than 13.2 g/dL for men and 11.6 g/dL for women) necessitate medical ...

Protagonist Therapeutics has 2 attractive late-stage pipeline assets, but commercialized sales will not begin until 2027.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of ...

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other ...